

SCIENTIFIC REPORTS



OPEN

Striatal Neurons Expressing D₁ and D₂ Receptors are Morphologically Distinct and Differently Affected by Dopamine Denervation in Mice

D. Gagnon, S. Petryszyn, M. G. Sanchez, C. Bories, J. M. Beaulieu, Y. De Koninck, A. Parent & M. Parent

Received: 20 September 2016

Accepted: 19 December 2016

Published: 27 January 2017

The loss of nigrostriatal dopamine neurons in Parkinson's disease induces a reduction in the number of dendritic spines on medium spiny neurons (MSNs) of the striatum expressing D₁ or D₂ dopamine receptor. Consequences on MSNs expressing both receptors (D₁/D₂ MSNs) are currently unknown. We looked for changes induced by dopamine denervation in the density, regional distribution and morphological features of D₁/D₂ MSNs, by comparing 6-OHDA-lesioned double BAC transgenic mice (*Drd1a*-tdTomato/*Drd2*-EGFP) to sham-lesioned animals. D₁/D₂ MSNs are uniformly distributed throughout the dorsal striatum (1.9% of MSNs). In contrast, they are heterogeneously distributed and more numerous in the ventral striatum (14.6% in the shell and 7.3% in the core). Compared to D₁ and D₂ MSNs, D₁/D₂ MSNs are endowed with a smaller cell body and a less profusely arborized dendritic tree with less dendritic spines. The dendritic spine density of D₁/D₂ MSNs, but also of D₁ and D₂ MSNs, is significantly reduced in 6-OHDA-lesioned mice. In contrast to D₁ and D₂ MSNs, the extent of dendritic arborization of D₁/D₂ MSNs appears unaltered in 6-OHDA-lesioned mice. Our data indicate that D₁/D₂ MSNs in the mouse striatum form a distinct neuronal population that is affected differently by dopamine deafferentation that characterizes Parkinson's disease.

The striatum is the main input structure as well as the largest integrative component of the basal ganglia. It receives a multitude of neurochemical inputs that are largely processed by striatal projection neurons. At the somatodendritic level, these cells form a rather morphologically homogeneous population, each element being endowed with a medium-sized cell body and typical spiny dendrites. These so-called medium spiny neurons (MSNs) all use γ -aminobutyric acid (GABA) as a neurotransmitter and represent approximately 90–95% of the striatal neuronal population in rodents¹. Despite their morphological similarities, MSNs can be divided into two subpopulations based on their neurochemical content and axonal projection sites. Roughly half of the MSNs express dopamine (DA) receptor of the D₁ type and contain the neuropeptides substance P (SP) and dynorphin (DYN). They innervate mainly the substantia nigra *pars reticulata* and the entopeduncular nucleus (rodent homologue of primate internal pallidum) and form the so-called “direct pathway”. The other half of the MSNs expresses DA receptor of the D₂ type and contains the neuropeptide enkephalin (ENK). Their axon arborizes principally in the pallidum (rodent homologue of primate external pallidum) and forms the first segment of the so-called “indirect pathway”^{2–5}. However, it is worth noting that single-axon tracing experiments in rodents⁶ and primates⁷ indicate that most striatofugal axons arborize into the three main striatal targets. To this regards, it has recently been shown that both D₁ and D₂ MSNs located in the nucleus accumbens (Acb) can either inhibit or disinhibit thalamic activity depending on their projection pattern and not on their genetic characteristics⁸.

The D₁ and D₂ receptors are reportedly co-expressed in a certain proportion of MSNs, but the size of such D₁/D₂ subpopulation is still a matter of controversy. Earlier studies undertaken with *in situ* hybridization methods, immunohistochemistry or reverse transcription polymerase chain reaction have reported high percentages of striatal neurons expressing both DA receptors^{3,9–17}, but a much smaller number of D₁/D₂ MSNs was detected in transgenic mice expressing fluorescent reporters for D₁ or D₂^{18–21}.

Centre de recherche de l'Institut universitaire en santé mentale de Québec, Department of Psychiatry and Neuroscience, Faculty of medicine, Université Laval, Quebec City, QC, Canada. Correspondence and requests for materials should be addressed to M.P. (email: martin.parent@fmed.ulaval.ca)

When co-expressed by MSNs, the D₁ and the D₂ receptors are reportedly able to form heteromers, the activation of which can lead to a distinct intracellular signalling pathway^{22–26}. The independent activation of the D₁ or the D₂ DA receptor is known to differentially regulate cyclic-AMP activity, respectively leading to the activation (D₁ coupled to G_s) or inhibition (D₂ coupled to G_i) of MSNs^{27,28}. In contrast, the activation of D₁/D₂ heteromers would result in a distinct phospholipase C-mediated calcium signalling through activation of G_q protein^{22–25}. However, while co-expression of D₁ and D₂ receptors is well accepted, the existence of D₁/D₂ heteromers *in vivo* remains controversial^{29,30}.

The fate of MSNs expressing D₁ or D₂ DA receptor in the context of DA striatal deafferentation that characterizes Parkinson's disease (PD) has already been studied. In a mouse model of PD, lesion of the striatal DA input was shown to induce spine pruning, principally on the D₂ MSNs^{31,32} and less markedly on the D₁ MSNs^{31–35}. Such spine pruning appears to be a highly plastic phenomenon since the reduction of spine density observed on the D₂ MSNs, but not that on D₁ MSNs, could be restored by long-term administration of L-Dopa^{33,35}. Reduction in the number of dendritic spine of striatal MSNs has also been reported in non-human primate model of PD³⁶ and in PD patients^{37–39}. Surprisingly, the fate of MSNs expressing both the D₁ and the D₂ DA receptors (the D₁/D₂ MSNs) has never been investigated in PD condition. Therefore, we have designed a study to provide the first detailed description of changes induced by DA denervation in the density, regional distribution and fine morphological characteristics of dendritic processes of D₁/D₂ MSNs that populate the dorsal striatum and the Acb, the main component of the ventral striatum, of mice. Using stereological approaches and single-neuronal injections performed on striatal sections from sham and 6-hydroxydopamine (6-OHDA)-lesioned double BAC transgenic mice (*Drd1a*-tdTomato/*Drd2*-EGFP), we show that the D₁/D₂ MSNs are affected differently than the D₁ and D₂ MSNs by striatal DA deafferentation that characterizes PD.

Results

Unilateral 6-OHDA injections cause severe TH+ cell loss in the SNc and VTA, significant DA depletion in the striatum and in the Acb and spontaneous ipsilateral rotations. Immunolabeling of the striatum and the substantia nigra *pars compacta* (SNc) for the DA transporter (DAT) and tyrosine hydroxylase (TH) indicate a severe DA lesion caused by 6-OHDA unilateral injections performed in the medial forebrain bundle (Fig. 1). Counts of TH+ cell bodies in the midbrain show a more severe DA cell loss in the SNc compared to the VTA (80.7 ± 7.5% decrease in SNc vs. 48.9 ± 9.2% decrease in VTA, compared to control side, Fig. 1a,b). LI-COR® slide scanner measurements indicate an average of 81.3% decrease of TH and 87.5% of DAT immunoreactivity in the dorsal striatum when compared to control side as well as a 80.1% reduction of TH and a 79.3% decrease of DAT immunoreactivity in the Acb, when compared to control side (Fig. 1c,d). Behavioral assessments show a significant preference for spontaneous rotations ipsilateral to the lesioned side in mice that were unilaterally injected with 6-OHDA (57.1 ± 6.4 spontaneous ipsilateral rotations/10 min vs. 1.1 ± 0.8 contralateral rotations, *P* < 0.0001, Fig. 1e).

The D₁/D₂ MSNs contain dynorphin but not enkephalin. Examination of ENK and DYN-immunostained sections from colchicine-treated mice reveals that, as expected, D₁ MSNs are immunoreactive for DYN but not for ENK. In contrast, D₂ MSNs contain ENK but are devoid of DYN. In regard to D₁/D₂ MSNs, they are immunopositive for DYN but immunonegative for ENK (Fig. 2).

D₁/D₂ MSNs are homogeneously distributed throughout the dorsal striatum but heterogeneously scattered in the nucleus accumbens. The regional distribution of D₁, D₂ and D₁/D₂ MSNs in the dorsal striatum of sham mice was estimated stereologically. The overall densities of D₁ and D₂ MSNs are 108 ± 5 and 95 ± 4 × 10³ cells/mm³, representing respectively 52.2 ± 1.1% and 45.9 ± 1.1% of the total MSNs population of the striatum. In contrast, the D₁/D₂ MSNs have a much lower density with only 3.8 ± 0.3 × 10³ cells/mm³ (*P* < 0.0001), representing 1.9 ± 0.2% of the striatal MSNs. Although not statistically significant (*P* = 0.2341), the density of the D₁/D₂ MSNs in the ventromedial sector of the striatum was lower in the post-commissural striatum (1.8 ± 0.4 × 10³ cells/mm³) than in the pre-commissural striatum (4.3 ± 0.3 × 10³ cells/mm³). Statistical evaluations (ANOVA) of neuronal densities in different striatal regions reveal no statistical differences (Fig. 3), supporting the homogeneous regional distribution of the D₁, D₂ and D₁/D₂ MSNs throughout the dorsal striatum. Occasionally, some D₁/D₂ MSNs can be seen to form small clusters of 2–3 cells at different striatal levels. Assessment of the distribution of D₁/D₂ MSNs in striosomes and matrix striatal compartments, as delineated on immunostained sections for μ-opioid receptor, reveals no significant difference, neither at the pre-commissural level (*P* = 0.4857), nor at the post-commissural level (*P* = 0.8286, Fig. S1). Our quantitative analyses reveal that the D₁/D₂ MSNs are more heterogeneously distributed in the Acb than in the dorsal striatum. As shown in Fig. 4d, a dense region located in the medial part of the shell of the Acb was almost entirely composed of the D₁/D₂ type of MSNs. A closer examination of the lateral striatal stripe indicates no significant difference regarding the density of the D₁/D₂ MSNs compared to other regions of the lateral area of the shell of the Acb. The density of the D₁/D₂ MSNs is overall significantly higher in the Acb compared to the striatum. This difference becomes statistically significant in the shell compartment of the Acb with 45.0 ± 10.9 × 10³ cells/mm³ compared to 3.8 ± 0.3 × 10³ cells/mm³ in the dorsal striatum (*P* = 0.0098, Fig. 3c). Our stereological estimations indicate that the D₁/D₂ MSNs represent 14.6 ± 3.0% of the MSN population in the shell and 7.3 ± 2.2% in the core compartment of the Acb, percentages that are significantly higher than what was noted in the dorsal striatum (1.9 ± 0.2%, *P* = 0.0098). Interestingly, the density of the D₁ MSNs is also higher in the shell of the Acb when compared to the dorsal striatum (180.0 ± 13.6 vs. 108.2 ± 5.4 × 10³ cells/mm³, *P* = 0.0244, Fig. 3a) whereas no difference is noted regarding the density of the D₂ MSNs between the dorsal striatum and the Acb. A higher density of the D₁ and the D₁/D₂ MSNs in the Acb is congruent with an overall higher density of all MSNs in the shell (298.6 ± 15.0) and the core (267.9 ± 24.5 cells/mm³) compartments of the Acb compared to the dorsal striatum (123.5 ± 5.4 × 10³ cells/mm³).




Figure 1. Assessment of the dopaminergic lesion induced by 6-OHDA injection in the medial forebrain bundle. (a) Transverse section taken through the substantia nigra *pars compacta* (SNc) and the ventral tegmental area (VTA) that was immunostained for tyrosine hydroxylase (TH) to assess the dopaminergic lesion induced by stereotaxic injection of 6-OHDA in the right medial forebrain bundle. (b) Histogram showing the percentage of TH+ cell loss in the SNc and the VTA, as expressed in percentage of intact side. (c) Transverse section taken through the striatum (STR) and immunostained for TH. (d) Histogram showing immunoreactivity of the STR and the nucleus accumbens (Acb) for the tyrosine hydroxylase (TH) and the dopamine transporter (DAT) in the 6-OHDA-lesioned side, as expressed in percentage of intact side. (e) Behavioural response induced by 6-OHDA lesion, as shown in number of contralateral and ipsilateral spontaneous rotations observed in 10 minutes. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ for intact side vs. 6-OHDA-lesioned side, **** $P < 0.0001$ for ipsilateral vs. contralateral rotations, by Mann-Whitney test.

The striatal D₁/D₂ MSNs display a smaller cell body and a shorter dendritic arborization than the two other types of MSNs. In sham animals, the cell body of dorsal striatum D₁/D₂ MSNs injected with Lucifer yellow are smaller than those of the D₁ and the D₂ MSNs: the mean diameter of the D₁/D₂ MSN




Figure 2. Neurochemical content of the D₁/D₂ MSNs. Transverse sections taken from the dorsolateral striatum of a D₁/D₂ transgenic mouse that were immunostained for enkephalin (ENK, a–d) or dynorphin (DYN, e–h). Thin arrows indicate D₁ MSNs, thick arrows point to D₂ MSNs and arrowheads to D₁/D₂ MSNs. The D₁/D₂ MSNs are immunoreactive for dynorphin but not for enkephalin in the D₁/D₂ transgenic mouse.

perikarya is $12.5 \pm 0.4 \mu\text{m}$ compared to $14.3 \pm 0.4 \mu\text{m}$ for the D₁ ($P = 0.0094$) and to $15.0 \pm 0.5 \mu\text{m}$ for the D₂ MSNs ($P = 0.0009$). The reconstruction of somatodendritic domains of Lucifer yellow-filled MSNs reveals that the total dendritic length of D₁/D₂ MSNs is also smaller than that of the D₁ and the D₂ MSNs. The mean total dendritic length for the D₁/D₂ MSNs is $0.75 \pm 0.06 \text{ mm}$ compared to $1.48 \pm 0.13 \text{ mm}$ for D₁ ($P < 0.0001$) and $1.08 \pm 0.08 \text{ mm}$ for D₂ MSNs ($P = 0.0296$, Fig. 5a). We also noted that the dendritic arborization of the D₁ MSNs is significantly longer than that of the D₂ MSNs ($P = 0.0089$). The dendritic arborization of the D₁/D₂ MSNs is significantly less profuse than that of the D₁ and D₂ MSNs, as indicated by a smaller number of dendritic branching points (9.5 ± 0.8 branching points) compared to the D₁ (16.6 ± 1.5 branching points, $P = 0.0015$) and the D₂ MSNs (15.0 ± 1.4 branching points, $P = 0.0087$, Fig. 5b).

D₁/D₂ MSN dendrites harbor fewer spines than the two other types of MSNs. By dividing the number of spines by the total dendritic length for each reconstructed neuron in sham animals, we were able to evaluate the overall spine density for each of the three types of striatal MSNs. Our data reveal that the D₁/D₂ MSNs have a 37% lower spine density (4.0 ± 0.2 spines/ $10 \mu\text{m}$) than the D₁ (6.4 ± 0.3 spines/ $10 \mu\text{m}$, $P < 0.0001$) and the D₂ (6.6 ± 0.2 spines/ $10 \mu\text{m}$, $P < 0.0001$) MSNs (Fig. 5c). A Sholl analysis performed on all reconstructed neurons indicates that this lower spine density is maintained throughout the entire dendritic extent of the D₁/D₂ MSNs, the difference being statistically significant on a distance ranging between 45 and 105 μm from their parent cell bodies (Fig. 5d).

The density of D₁/D₂ MSNs is unaltered in 6-OHDA-lesioned mice. In 6-OHDA mice, the density of the D₁/D₂ MSNs in the dorsal striatum was $3.8 \pm 0.3 \times 10^3$ cells/ mm^3 , accounting for $2.1 \pm 0.2\%$ of total MSN population. In comparison, the density of the D₁ and the D₂ MSNs was $108.2 \pm 5.4 \times 10^3$ cells/ mm^3 and $94.9 \pm 4.1 \times 10^3$ cells/ mm^3 , representing $53.5 \pm 1.0\%$ and $44.4 \pm 1.1\%$ of the total MSN population, respectively (Fig. 3). There is no statistically significant difference between sham and 6-OHDA-lesioned animals in regard to these figures. Likewise, assessment of MSN densities in the Acb does not reveal any significant differences between the sham and 6-OHDA-lesioned animals (Fig. 3). The density of the D₁/D₂ MSNs obtained in the shell compartment of the Acb of 6-OHDA-lesioned mice was $29.7 \pm 6.0 \times 10^3$ cells/ mm^3 whereas the neuronal density of D₁ and D₂ MSNs in the same experimental group were 193.1 ± 8.7 and $104.7 \pm 5.7 \times 10^3$ cells/ mm^3 , respectively. Values obtained in the core compartment of the Acb of 6-OHDA-lesioned mice reach 11.9 ± 1.4 , 168.4 ± 13.8 and $102.9 \pm 13.6 \times 10^3$ cells/ mm^3 for the D₁/D₂, D₁ and D₂ MSNs, respectively (Fig. 3).

The extent of D₁/D₂ MSN dendritic arborization is unaffected by 6-OHDA lesion, in contrast to that of D₁ and D₂ MSNs. Statistical comparison between sham and 6-OHDA-lesioned mice in regard to the extent of somatodendritic domain belonging to the D₁, D₂ and D₁/D₂ MSNs in the dorsal striatum indicates that the total dendritic length of the D₁ MSNs was reduced in the DA-depleted striatum by 60% (0.60 ± 0.04 vs. $1.48 \pm 0.13 \text{ mm}$, $P < 0.0001$, Fig. 6a) and by 28% for the D₂ MSNs (0.78 ± 0.09 vs. $1.08 \pm 0.08 \text{ mm}$, $P = 0.0191$, Fig. 6b). Surprisingly, no significant differences between sham and 6-OHDA-lesioned mice were observed regarding the total dendritic length of the D₁/D₂ MSNs (0.61 ± 0.05 vs. $0.75 \pm 0.07 \text{ mm}$, $P = 0.6356$, Fig. 6c). Accordingly, in 6-OHDA-lesioned mice, a lower number of dendritic branching points were observed for the D₁ MSNs (8.7 ± 0.7 vs. 16.6 ± 1.5 branching points, $P < 0.0001$) and the D₂ MSNs (10.7 ± 0.9 vs. 15.0 ± 1.4 branching points, $P = 0.0120$) but not for the D₁/D₂ MSNs with 9.5 ± 0.8 branching points in both experimental groups ($P > 0.9999$).




Figure 3. Densities of D_1 , D_2 and D_1/D_2 MSNs in sham and 6-OHDA-lesioned mice. Histograms showing the density of D_1 (a), D_2 (b) and D_1/D_2 (c) MSNs in different regions of the striatum (STR) and the nucleus accumbens (Acb) of sham and 6-OHDA-lesioned mice. * $P < 0.05$, ** $P < 0.01$ vs. the shell compartment of the Acb and @ $P < 0.05$, @@ $P < 0.01$ vs. the core compartment of the Acb, by Kruskal-Wallis test.

The spine density on D_1/D_2 MSN dendrites is reduced in 6-OHDA-lesioned mice. Lesion of the striatal DA afferent projections leads to a significant decrease of spine density on dendrites belonging to the three types of MSNs. The overall spine density was 4.0 ± 0.4 spines/ $10 \mu\text{m}$ in 6-OHDA compared to 6.4 ± 0.3 in sham ($P < 0.0001$) for the D_1 MSNs; 5.1 ± 0.3 spines/ $10 \mu\text{m}$ compared to 6.6 ± 0.2 ($P = 0.0018$) for the D_2 MSNs and 3.0 ± 0.1 spines/ $10 \mu\text{m}$ compared to 4.0 ± 0.2 ($P = 0.0427$) for the D_1/D_2 MSNs. These reductions accounted for a 37.5% loss on the D_1 , 22.7% on the D_2 and 25.0% on the D_1/D_2 MSNs. The Sholl analysis indicates that such lower spine density is maintained throughout the entire dendritic arborization of the three types of MSNs (Fig. 7).

Discussion

The present study provides the first detailed description of the morphological characteristics, density and regional distribution of D_1/D_2 MSNs of the dorsal striatum and Acb in normal mice, as well as the first characterization of changes induced in this striatal subpopulation by striatal DA denervation. Our data gathered in normal animals reveal that the D_1/D_2 MSNs are morphologically distinct from the D_1 and D_2 MSNs: they have a smaller cell body, a less profusely arborized dendritic tree with branches that bear fewer spines than those of the D_1 and D_2




Figure 4. Regional distribution of D_1/D_2 MSNs in the dorsal striatum and the nucleus accumbens.

(a,b) Schematic representations of transverse sections taken at 0.26, -0.94 and 1.10 mm from bregma on which sectors that were sampled to provide unbiased stereological estimation of the number of D_1 , D_2 and D_1/D_2 MSNs in the striatum (STR, a) and the nucleus accumbens (Acb, b) are delineated. (c,d) Schematic representations of the distribution of D_1/D_2 MSNs at the pre and post-commissural level of the STR (c) as well as in the core (AcbC) and the shell (AcbSh) of the nucleus accumbens. The transverse section shown in (b) was immunostained for calbindin and used to delineate the AcbC from the AcbSh.

MSNs. They are uniformly scattered throughout the striatum, where they represent approximately 2% of the total number of MSNs, but heterogeneously distributed and more abundant in the Acb, where their proportion ranged from 7 to 15% of all MSNs. In 6-OHDA-lesioned mice, the density and regional distribution of all 3 types of MSNs is essentially unaltered. In contrast to the D_1 and the D_2 MSNs, the D_1/D_2 neurons do not show any significant reduction in the length of their dendritic arborization after intoxication with 6-OHDA. However, a reduction in dendritic spine density was noted in all three types of MSNs following DA depletion, but this pruning phenomenon was more prominent in the D_1 than in the D_2 or D_1/D_2 MSNs. The significance of these results will now be discussed in the light of relevant literature.

It is now well established that co-expression of D_1 and D_2 receptors occurs in some striatal MSNs, but there is still some controversy regarding the relative importance of such a unique neuronal population. In the literature, the percentage of striatal MSNs that coexpress D_1 and D_2 ranges from low^{2,10,11,24,40}, moderate^{12,14,41} to nearly 100%⁹. Such substantial differences may be explained, on one hand, by the various methods and species used and, on the other hand, by the specificity of the antibodies or the *in situ* hybridization probes employed to detect D_1 and D_2 receptors. In the present study, depending on striatal sectors that were examined, we estimate that the D_1/D_2 MSNs account for 0.8–2.4% of the total number of striatal MSNs, a proportion that agrees with figures reported in other studies conducted in BAC transgenic mice^{18,20,42}.

Despite that they represent only 2% of the total MSNs population of the adult mice dorsal striatum, the D_1/D_2 MSNs might play an important role in striatal functioning, as it is the case of striatal interneurons, which account




Figure 5. Dendritic domains of the D₁, D₂ and D₁/D₂ MSNs in sham-lesioned mice. (a–c) Histograms showing the total dendritic length (a), the number of dendritic branch points (b) and the overall spine density (c) of the D₁ (red), the D₂ (green) and the D₁/D₂ (yellow) striatal MSNs in sham-lesioned mice. (d) Sholl analysis of spine density of the 3 types of MSNs, as measured in sham-lesioned mice. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ for D₁ vs. D₂ vs. D₁/D₂ by One-way (a–c) or Two-way (d) ANOVA, followed by Bonferroni’s multiple comparison test.

only for 2–3% of striatal neurons in rodents^{43,44}. Their presence throughout the dorsal striatum suggest that the D₁/D₂ MSNs are involved in the sensorimotor and associative functions of the striatum, which are integrated mainly within the caudolateral and the rostromedial sector of the structure, respectively⁴⁵. However, the prevalence of the D₁/D₂ MSNs in the Acb indicates that these neurons are even more actively implied in the limbic aspect of striatal functioning. Indeed, we found the density of D₁/D₂ MSNs in the Acb to be significantly higher than in the dorsal striatum, a finding that is congruent with data from previous studies conducted in transgenic mice^{20,21,24,46,47} and by a higher number of D₁/D₂ heteromer in the rat and monkey Acb^{25,26}. The shell compartment of the Acb was significantly more enriched in D₁/D₂ MSNs than the core compartment, supporting the notion that the latter is more similar to the dorsal striatum than the former, which has been described as a transition zone between the striatum and the extended amygdala⁴⁸. The fact that the D₁/D₂ MSNs form the vast majority of MSNs in the medial area of the shell compartment, as noted here, is interesting since this medial region of the Acb shell is known to be involved in feeding behaviors^{49–52} as well as in the response to noxious stimuli⁵². Whether or not the D₁/D₂ MSNs present in the Acb play a role in the antidepressant and anxiolytic effects observed after disruption of the D₁-D₂ complex⁵³ remains to be investigated.

Besides their difference in the expression of DA receptors, the two major types of striatal MSNs express different neuropeptides in both rodents and primates^{2,14,54}, the D₁ MSNs containing SP and DYN while the D₂ MSNs are enriched with ENK²⁰. As for the D₁/D₂ MSNs, a previous report has suggested that they express both ENK and DYN in the rat²⁴, whereas the present findings clearly show that they display immunoreactivity only for DYN. Such a discrepancy might reflect a species difference, but most likely results from a variation in the methodological approach. We used highly specific transgenic fluorescent reporters to identify the D₁, D₂ and D₁/D₂ striatal MSNs, whereas Perreault, *et al.*²⁴ employed antibodies against the D₁ and D₂ receptors, which are known to be also highly expressed in the striatal neuropil, a situation that might have hampered the proper identification of




Figure 6. Dendritic arborization of the D_1 , D_2 and D_1/D_2 MSNs in 6-OHDA-lesioned mice. Histograms showing the total dendritic length and the number of dendritic branch points in sham (plain columns) and 6-OHDA (hatched columns) lesioned mice. The center and right columns provide schematic representations of D_1 (red), D_2 (green) and D_1/D_2 (yellow) MSNs dendritic arborization in sham (center column) and 6-OHDA (right column) lesioned mice. * $P < 0.05$, **** $P < 0.0001$ for sham vs. 6-OHDA-lesioned mice, by Student's T-test.

the various peptide expressing MSNs. Our data indicate that, in regard to neuropeptide content, the striatal D_1/D_2 neurons in mice have more in common with the D_1 than with the D_2 MSNs.

This first detailed report on the morphological organization of D_1/D_2 MSNs reveals that these neurons have a smaller cell body and a shorter dendritic tree than their D_1 or D_2 counterparts. Our data also underline the less profuse dendritic arborization of the D_2 compared to the D_1 MSNs, a morphological feature that might explain, at least in part, why the D_2 MSNs are more excitable than D_1 MSNs⁵⁵. Based on the morphology of their somato-dendritic domains, it is tempting to speculate that the excitability and input resistance of the D_1/D_2 MSNs would be higher than the D_1 or even the D_2 MSNs, but such a view needs to be confirmed by detailed investigations of electrophysiological properties of the D_1/D_2 MSNs.

In addition to a smaller dendritic tree, the D_1/D_2 MSNs also contain less dendritic spines than D_1 and D_2 MSNs. The head of dendritic spines is the preferential synaptic contact site of glutamatergic corticostriatal projections arising from the cerebral cortex and the intralaminar thalamic nuclei⁵⁶. With their less profuse dendritic arborization, the D_1/D_2 MSNs might receive significantly less glutamatergic input and thus be less vulnerable to excitotoxicity involved in different neuropathological conditions such as Huntington's disease. More importantly in the context of the present study is the spatial distribution of DA terminals in contact with different parts of the MSNs. Those terminals that contact the cell body and proximal dendritic shafts might produce a relatively non-specific effect mediated by the volumic release of DA⁵⁷. In contrast, as suggested Freund and colleagues⁵⁸, the major DA input that occurs on the necks of dendritic spines is likely to be much more selective since it could prevent the excitatory glutamatergic input to the same spines from reaching the dendritic shaft. One of the main functions of striatal DA release might be to alter the pattern of firing of striatal output neurons by regulating their input⁵⁸.




Figure 7. Dendritic spine density of the D_1 , D_2 and D_1/D_2 MSNs in sham and 6-OHDA-lesioned mice. Sholl analysis of spine density (left column) and histograms showing the overall spine density (center column) of the D_1 (a), red), D_2 (b), green) and D_1/D_2 (c), yellow) striatal MSNs in sham (circles and plain columns) and 6-OHDA (square and hatched columns) lesioned mice. The right column provides representative examples of dendritic segments belonging to the D_1 , D_2 or D_1/D_2 MSNs that were filled with Lucifer yellow in sham and 6-OHDA-lesioned mice. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ for sham vs. 6-OHDA by a Student's T-test (histograms) or Two-way ANOVA followed by Bonferroni's multiple comparison test (Sholl analysis).

Lesions with 6-OHDA in rats were shown to increase the expression of D_2 and decrease that of D_1 by MSNs⁵⁹. Here we report that the density and regional distribution of D_1/D_2 MSNs in mice striatum are unaltered by 6-OHDA lesions, suggesting that DA denervation does not alter the D_1 expression by D_2 MSNs or the D_2 expression by D_1 MSNs. However, it should be noted that the BAC transgenic reporter system used here does not fully allow to rule out the possibility that DA lesion may induce more subtle variations of DA receptor gene expression or receptor trafficking and degradation that could have remained undetected. The D_1/D_2 MSNs do not display any reduction of their dendritic tree following 6-OHDA lesions, in contrast to D_1 and D_2 MSNs, but the D_1/D_2 MSNs show a lower dendritic spine density in the DA-denervated striatum, as it is also the case for D_1 and D_2 MSNs. Reduction of the dendritic length of D_1 and D_2 MSNs following DA lesion is supported by observations gathered in mice^{34,35}, monkeys³⁶ and PD patients³⁷⁻³⁹. However, some studies in rats⁶⁰ and mice³³ failed to demonstrate such a phenomenon. The time between DA lesion and animal sacrifice might explain such a discrepancy. The interval between 6-OHDA injection and animal perfusion in the latter two studies ranged from 4 to 5 weeks, whereas the delay was much longer (8 weeks) in the present study. In face of such differences, it is tempting to speculate that the reduction in dendritic length occurs after the spine loss has occurred, that is in the late stages of the disease.

We documented spine loss for the three types of striatal MSNs, in accordance with data obtained for D_1 and the D_2 MSNs in mice^{33,35,61}, rats^{60,62,63}, monkeys³⁶ and PD patients^{37,38}. Interestingly, other studies have suggested that such spine loss may be restricted to the D_2 MSNs in mice^{31,32}. As mentioned above, DA axons are ideally

positioned on the dendritic spine neck to influence the effect of corticostriatal and thalamostriatal glutamatergic input⁵⁶. It has been hypothesized that the loss of DA afferents may destabilize the morphological integrity of the spine, potentially leading to spine pruning, a phenomenon that might be the result of maladaptive calcium influx through the L-type calcium channels located on MSNs³¹. Moreover, evidence has recently been gathered regarding the implication of acetylcholine, the level of which is known to be increased in PD^{64,65}, in spine pruning of the D₂ MSNs through the modulation of Kir2 channels, leading to an increase of dendritic excitability driven by the activation of M1 muscarinic receptor³².

The exact function of the D₁/D₂ MSNs of the striatum remains elusive. Colocalization of the D₁ and D₂ DA receptors has been reported in axons located in various basal ganglia components²⁴. Whether this observation indicates a distinct striatofugal pathway remains unclear⁶⁶. However, the existence of such unique striatofugal projections would imply a complementary functional role of the D₁/D₂ MSNs, working in concert with the D₁ and the D₂ MSNs for harmonious basal ganglia functioning. Single-axon tracing studies in rodents^{6,67} and monkeys^{7,68} have emphasized the highly collateralized nature of the striatofugal projections, challenging the concept of a simple dual (direct/indirect) striatofugal system. Whether the D₁/D₂ MSNs contribute to these highly collateralized striatofugal projections is currently unknown and single-axon tracing of D₁/D₂ MSNs is obviously needed to better appreciate their functional role in the basal ganglia functioning.

Methods

Animals. This study was carried out on 25 double BAC transgenic mice (*Drd1a*-tdTomato/*Drd2*-EGFP) of 2 month old weighing between 20–30 g. Equal numbers of male and female were used. These D₁/D₂ mice were generated by breeding B6SJL-F1-D₁tdTomato BAC transgenic mice¹⁹ with C57Bl6J-D₂-EGFP BAC animals⁶⁹. They allow direct identification of the D₁, D₂ and D₁/D₂ MSNs (Fig. 8). In order to minimize over expression artifacts, all mice were heterozygous for each individual BAC transgene. Animals were housed under a 12 h light-dark cycle with water and food ad libitum. All procedures were approved by the *Comité de Protection des Animaux de l'Université Laval*, in accordance with the Canadian Council on Animal Care's Guide to the Care and Use of Experimental Animals (Ed2) and with the ARRIVE guidelines. Maximum efforts were made to minimize the number of animals used.

Stereotaxic injections. *6-OHDA unilateral injection and behavioral assessment.* Nineteen *Drd1a*-tdTomato/*Drd2*-EGFP transgenic mice received an intracerebral injection of 6-OHDA (catalog no. H4381; Sigma-Aldrich, Saint-Louis, MO, USA) in the right medial forebrain bundle (mfb). Approximately 30 minutes before 6-OHDA administration, mice received intraperitoneal injection of desipramine (25 mg/kg) diluted in saline (0.9%) at a concentration of 2 mg/mL. Mice were then anaesthetized using 2% isoflurane and their head were fixed in a stereotaxic apparatus. A hole was drilled and the following stereotaxic coordinates were aimed: anteroposterior (bregma) = −1.2 mm; mediolateral = 1.1 mm; dorsoventral = −5.0 mm, corresponding to the mfb, according to the mouse brain atlas of Franklin and Paxinos⁷⁰. A glass micropipette of 35 μm diameter at the tip containing a freshly prepared 6-OHDA solution was introduced in the mfb. The 6-OHDA was then pressure-injected and the micropipette was left in place for 2 min both prior and following the injection. The 6-OHDA was diluted in ascorbic acid (catalog no. A5960; Sigma-Aldrich) at a concentration of 6 μg/μL. A total volume of 0.25 μL of 6-OHDA, corresponding to a dose of 1.5 μg of the neurotoxin, was injected into the right mfb. The sham-lesioned group was composed of 4 mice that only received injections of the vehicle (0.02% ascorbic acid). After surgery, the skin was sutured and mice were allowed to recover.

Thirty days after surgery, mice from the two experimental groups were introduced in a large glass cylinder and spontaneous motor behavior was recorded during 10 min. Spontaneous rotations were counted by a blinded experimenter. Complete ipsilateral and contralateral rotations to the 6-OHDA-lesioned side were counted and used as behavioral indication of the severity of the DA lesion.

Fifty-six days after the 6-OHDA lesion, animals were deeply anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). They were transcardially perfused with an initial wash of 40 mL of ice-cold sodium phosphate-buffered saline (PBS, 0.1 M; pH 7.4), followed by 150 mL of paraformaldehyde (PFA, 4% diluted in phosphate buffer). Brains were dissected out, post-fixed for 24 h in a 4% PFA solution and cut with a vibratome (model VT1200; Leica, Germany) into 50 μm-thick coronal sections, which were serially collected in sodium phosphate-buffered saline (PBS, 0.1 M, pH 7.4). The pre and post-commissural parts of the striatum were cut at 50 μm and used for immunohistochemistry and stereology whereas the commissural part was cut at 250 μm for intracellular injections.

Bilateral colchicine injections. Two other double BAC transgenic mice received bilateral injections of colchicine (catalog no. C9754; Sigma-Aldrich) in the striatum, a drug that block axonal transport, allowing optimal immunostaining of neuropeptides contained in MSNs cell bodies. For intra-cerebral injections of colchicine, the following stereotaxic coordinates were used: anteroposterior (bregma) = 0.14 mm; mediolateral = 2.00 mm; dorsoventral = 3.20 mm, corresponding to the dorsal part of the striatum at the commissural level, according to the mouse brain atlas of Franklin and Paxinos⁷⁰. One μL of colchicine diluted at 23 mg/mL in saline was pressure-injected in each side of the brain. One week after injections, colchicine-injected mice were transcardially perfused, as described above. Their whole brains were dissected out and cut with a vibratome into 50 μm-thick transverse sections.

Immunohistochemistry. *TH and DAT immunohistochemistry.* To assess the extent of the DA lesion induced by 6-OHDA injections, one 50 μm-thick section was selected from the pre-commissural striatum (0.14 mm from bregma) and from the SNc (−3.52 mm from bregma), in each mouse. These sections were immunostained for TH, the catalytic enzyme of DA synthesis, by using a polyclonal antibody (catalog no. AB152;




Figure 8. D_1/D_2 double BAC transgenic mice. Confocal images from the *Drd1a*-tdTomato/*Drd2*-EGFP double BAC transgenic mice (D_1/D_2) in which the expression of a red fluorescent protein (tdTomato) is under control of the D_1 promoter and the expression of a green fluorescent protein (EGFP) is under control of the D_2 promoter. (a) Confocal image of a sagittal section from a D_1/D_2 transgenic mouse taken through the striatum (STR) and the substantia nigra (SN). (b) Example of a Lucifer yellow-injected MSN located in the dorsal STR. (c–e) High magnification of striatal MSNs that contain the D_1 (red, thin arrows), the D_2 (green, thick arrows) or both D_1/D_2 (yellow, arrowheads) dopamine receptors.

Millipore Corporation, Billerica, USA) raised in rabbit. Briefly, the free-floating sections were sequentially incubated in (i) a blocking solution of PBS containing 2% normal goat serum and 0.01% Triton X-100 (1 h, RT); (ii) the same solution containing a 1/1000 dilution of rabbit polyclonal antibody against TH (overnight, 4 °C); and (iii) a 1/500 solution of biotinylated goat anti-rabbit (catalog no. BA-1000; Vector Laboratories, Burlingame, CA, USA) diluted in the same blocking solution (2 h at room temperature (RT)). After rinses in PBS, sections were incubated for 1 h at RT in an avidin-biotin-peroxydase complex solution (Vector Laboratories) diluted 1/100 in the blocking solution. Sections were then rinsed and the bound peroxidase revealed by incubating the sections for 3 min at RT in a 0.025% solution of 3,3'-diaminobenzidine tetrahydrochloride (DAB; catalog no. D5637; Sigma-Aldrich) diluted in Tris-buffered saline (TBS; 50 mM; pH 7.4), to which 0.005% of H_2O_2 was added. The reaction was stopped and the sections mounted on gelatin-coated slide and air-dried. Sections were then dehydrated in graded alcohol, cleared in toluene and coverslipped with Permount (catalog no. SP15-500; Fisher Scientific). The TH-immunostained sections taken through the midbrain were used to assess the number of DA

cell bodies in the SNc and VTA, as delineated based on the mouse brain atlas of Franklin et Paxinos⁷⁰. On these sections, all TH+ cell bodies were counted and results expressed as percentage of control side.

In each mouse, the DA lesion was also assessed using an infrared imaging system (Odyssey CLx; LI-COR Biosciences, Lincoln, NE, USA) from a 50 μm -thick section taken at the pre-commissural level of the striatum (1.34 mm from bregma). Sections were immunostained for TH and DAT, using secondary antibodies coupled to infrared fluorescent dyes. The primary antibody against TH was the same as above (1/1000, overnight at 4 °C). The monoclonal antibody against DAT (1/1000, overnight at 4 °C, catalog no. MAB369; EMD Millipore Corporation, Billerica, USA) was raised in rat. Donkey anti-rabbit 680 (1/1000, 2 h at RT, catalog no. 926-68073; LI-COR Biosciences) and goat anti-rat 800 (1/1000, 2 h at RT, catalog no. 926-32219; LI-COR Biosciences) were used as secondary antibodies. Two solid-state diode lasers (685 nm and 785 nm) were used to excite secondary antibodies coupled to infrared fluorescent dyes. Intensity values of TH and DAT immunoreactivity were taken from six 0.16 mm² squares randomly placed over the striatum and from one 0.16 mm² square placed over the Acb.

Calbindin immunohistochemistry. In order to precisely delineate the core and the shell regions of the Acb, transverse sections adjacent to those used for stereology were immunostained for calbindin (CB). Briefly, the immunoperoxidase protocol described above was used but with a monoclonal primary antibody against CB (1/500, overnight at 4 °C, catalog no. C-9848, Sigma-Aldrich) and a biotinylated horse anti-mouse secondary antibody (1/200, 2 h at RT, catalog no. BA-2000; Vector Laboratories).

μ -opioid receptor immunohistochemistry. In order to delineate the striosomes and matrix striatal compartments, 2 transverse sections were taken at the pre-commissural and post-commissural striatal levels and immunostained for μ -opioid receptor (MOR). These sections were used to assess differences in the density of D₁/D₂ MSNs between the 2 striatal compartments. Briefly, sections were incubated with a primary antibody against MOR (1/200, overnight at 4 °C, catalog no. AB5509; Chemicon, Darmstadt, Germany) followed by incubation into a donkey anti-guinea pig secondary antibody coupled to Cy5 (1/200, 2 h at RT, catalog no. 706-175-148; Jackson ImmunoResearch, West Grove, PA, USA).

Enkephalin and dynorphin immunohistochemistry. Neuropeptide content of the D₁, D₂ and D₁/D₂ MSNs was assessed on singly labeled sections for ENK or DYN, taken from the 2 colchicine-injected mice. Briefly, sections were incubated with either a mouse anti-ENK (1/50, NOC1; Mediacorp, Montreal, QC, Canada) or a rabbit anti-DYN (1/200, catalog no. SP1215; Acris, San Diego, CA, USA) antibody overnight at 4 °C. Sections were then incubated with either a horse anti-mouse (1/200, catalog no. BA-2000; Vector Laboratories) biotinylated secondary antibodies for 2 h at RT, followed by streptavidin-Cy5 (1/200, catalog no. SA1011; Invitrogen, Carlsbad, CA, USA) for 1 h at RT in the case of ENK, or directly with a goat anti-rabbit-Cy5 (1/200, catalog no. 111-175-003; Jackson ImmunoResearch) for 2 h at RT in the case of DYN. Images were acquired using a confocal microscope (Zeiss, LSM 700; Oberkochen, Germany).

Quantitative assessment of D₁, D₂ and D₁/D₂ MSNs in the striatum. Four sham and 4 6-OHDA-lesioned mice were used for stereological estimation of the number of D₁, D₂ and D₁/D₂ MSNs. In each mouse, 6 sections were selected from the pre-commissural striatum. Three adjacent sections were selected at 0.26 mm from bregma and 3 others at 1.10 mm. Three more sections were taken at -0.94 mm from bregma. These sections were used to estimate the number of D₁, D₂ and D₁/D₂ MSNs in the pre-commissural (0.26 mm from bregma) and post-commissural striatum (-0.94 mm from bregma), as well as in the Acb (1.10 mm from bregma), with an unbiased stereological method using a confocal microscope equipped with a digital camera and a motorized stage controlled by a computer running the StereoInvestigator software (v. 7.00.3; MicroBrightField, Colchester, VT, USA). First, on each section, striatal contour was traced and 4 striatal sectors were delineated corresponding to a dorsolateral, dorsomedial, ventrolateral and ventromedial sectors (Fig. 4). The Acb was divided into its core and shell compartments based on CB-immunostained adjacent sections.

On each section, the striatum was entirely scanned through multiple Z-stacks using a 40x objective (NA 1.4, oil immersion, Plan-Apochromat, Zeiss) and the 488 and 568 diode lasers at 2% of power. Optical resolution of the Z-stacks was 512 × 512 pixel (pixel size = 0.10 μm^2), with Z-steps of 3 μm corresponding to the optical slice determined by the pinhole. The thickness of Z-stacks was fixed at 30 μm and the gain setting for each channel was kept constant during the entire acquisition process.

The process leading to the estimation of the total number of D₁ and D₂ MSNs began by randomly translating a grid formed by 235 × 580 μm rectangles on the previously acquired confocal images of the striatum and the Acb. At each intersection of the grid that fell into the sector, a counting frame measuring 157 × 157 μm was drawn and examined. Cell bodies containing tdTomato (D₁) or GFP (D₂) that fell inside the counting frame and did not contact the exclusion lines were counted whenever they came into focus within a 12 μm -thick optical disector placed at 9 μm from the top of the section. An average number of 2939 ± 186 D₁ and 2477 ± 160 D₂ neurons were counted in the striatum and 1187 ± 98 D₁ and 642 ± 64 D₂ cell bodies in the Acb of each mouse, yielding coefficient of error (Gundersen, m = 1) ranging between 0.05 and 0.18.

Because less numerous, the number of striatal cells containing both tdTomato (D₁) and GFP (D₂), here called the D₁/D₂ MSNs, was estimated with stereological parameters different from those employed to estimate the number of D₁ and D₂ MSNs. Selected transverse sections of the striatum were entirely examined with an optical disector of the same size of the one described above. An average of 599 ± 106 D₁/D₂ cells were counted in the striatum compared to 993 ± 191 D₁/D₂ neurons in the Acb of each mouse, yielding coefficient of error (Gundersen, m = 1) ranging between 0.08 and 0.27. The density of D₁, D₂ and D₁/D₂ MSNs was obtained by dividing the number of striatal cells estimated with the optical disector by the volume of striatal sectors sampled, as estimated with the Cavalieri's method⁷¹.

In the 4 sham-lesioned animals, the 2 transverse sections taken at the pre-commissural (0.26 mm from bregma) and post-commissural (−0.94 mm from bregma) striatal levels that were immunostained for MOR were used to estimate the number of D₁/D₂ MSNs in the striosomes and matrix compartments. Again, all striatal D₁/D₂ MSNs were counted from previously acquired confocal images and the striosomes and matrix compartments were delineated by using MOR immunoreactivity.

Single-cell injections of identified MSNs. Fine morphological changes of MSN dendritic arborization induced by DA denervation were characterized by single-neuronal injections of Lucifer yellow applied to PFA-fixed brain sections from the *Drd1a*-tdTomato/*Drd2*-EGFP transgenic mice, using a method previously described^{72,73}. Sharp heat-pulled glass micropipettes filled with a 4% solution of Lucifer yellow (catalog no. L453; Life Technologies, Carlsbad, CA, USA) and containing a silver electrode connected to a computer-controlled microelectrode amplifier (Multiclamp 700 A, Axon Instruments) were inserted into 250 μm-thick brain section kept in ice-cold PBS (0.1 M), under an epifluorescence microscope (model no. E600FM, Nikon, Tokyo). After the insertion of the micropipette into the soma of visually identified MSNs located in the dorsal striatum, a negative direct current of 5 nA was administered for 20 minutes during which MSNs were filled with the negatively charged Lucifer yellow tracer. A 488 nm filter was used to visualize GFP contained in D₂ MSNs whereas a 568 nm filter was used to detect the presence of tdTomato into D₁ MSNs. Each neurons being injected was carefully inspected with both filters in order to determine content in GFP and/or tdTomato with a 40X water immersion objective (NA 0.80). All injected MSNs were located in the dorsal striatal region, at the commissural level, and restricted to 0.02–0.26 mm in the anteroposterior axis relative to the bregma, 1–3 mm in the mediolateral axis and 2–3 mm in the dorsoventral axis, according to the stereotaxic mouse brain atlas⁷⁰.

The 250 μm-thick sections containing injected striatal neurons were mounted on glass slides and coverslipped with a fluorescence mounting medium (S3023; Dako, Mississauga, Ontario, Canada). Z-stack of Lucifer yellow-filled neurons were obtained from the confocal microscope using a 405 nm diode laser and a 63x oil immersion objective (NA 1.4, Plan-Apochromat, Zeiss). The pixel size was 0.001 μm² whereas the optical slicing was 0.3 μm. A tiling process was used when dendritic arborization extend beyond the field of view.

Morphological analysis of injected MSNs. Analyses of dendritic arborization and spine density were performed using the freely available *NeuronStudio* software (CNIC, Mount Sinai School of Medicine, New York, NY, USA). The entire somatodendritic domains of injected neurons were carefully reconstructed using maximum intensity projection in *NeuronStudio* software, as previously described⁷⁴. By using a combination of automatic spine detection from *NeuronStudio* software followed by a careful examination of individual spine, we were able to provide faithful three-dimensional reconstructions of somatodendritic domains of injected MSNs. From these reconstructions, Sholl analyses were performed on individual MSNs of the D₁, D₂ and D₁/D₂ types. Measurements of the size of the cell body were conducted by using the *ImageJ* software (Version 1.48). In this software, maximum intensity projections of Z-stacks were generated and diameters of cell bodies were measured. Dendritic arborization analyses and size measurements were performed on 19 D₁, 27 D₂, 20 D₁/D₂ Lucifer-yellow-injected MSNs from 4 sham-lesioned animals and on 18 D₁, 17 D₂ and 22 D₁/D₂ MSNs from 19 6-OHDA-lesioned mice.

Statistical analysis. Statistical differences of neuronal densities between different striatal and Acb regions were assessed using Kruskal-Wallis non-parametric statistical test. Differences between sham and 6-OHDA-lesioned mice regarding neuronal densities and spontaneous rotations were assessed with Mann-Whitney non-parametric test. Variations in immunoreactivity for TH and DAT between sham and 6-OHDA-lesioned mice were detected using the Mann-Whitney statistical test. A Sholl analysis with 15 μm increments was used to determine the spine density and statistical differences for dendritic morphology (number of branching points, spine density and dendritic length) and for cell body diameters between the two experimental groups and the three types of MSNs were assessed with the two-way analysis of variance (ANOVA) followed by a Bonferroni multiple comparison test. All statistical tests were performed using GraphPad Prism software (v. 6.01; GraphPad Software, San Diego, CA, USA). Mean and standard error of the mean are used throughout the text as central tendency and dispersion measure, respectively.

References

1. Graveland, G. A. & DiFiglia, M. The frequency and distribution of medium-sized neurons with indented nuclei in the primate and rodent neostriatum. *Brain Res* **327**, 307–311 (1985).
2. Gerfen, C. R. *et al.* D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. *Science* **250**, 1429–1432 (1990).
3. Le Moine, C. & Bloch, B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. *The Journal of comparative neurology* **355**, 418–426 (1995).
4. Wichmann, T. & DeLong, M. R. Models of basal ganglia function and pathophysiology of movement disorders. *Neurosurgery clinics of North America* **9**, 223–236 (1998).
5. Albin, R. L., Young, A. B. & Penney, J. B. The functional anatomy of disorders of the basal ganglia. *Trends in neurosciences* **18**, 63–64 (1995).
6. Wu, Y., Richard, S. & Parent, A. The organization of the striatal output system: a single-cell juxtacellular labeling study in the rat. *Neuroscience research* **38**, 49–62 (2000).
7. Lévesque, M. & Parent, A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 11888–11893 (2005).
8. Kupchik, Y. M. *et al.* Coding the direct/indirect pathways by D1 and D2 receptors is not valid for accumbens projections. *Nature neuroscience* **18**, 1230–1232 (2015).
9. Aizman, O. *et al.* Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. *Nature neuroscience* **3**, 226–230 (2000).

10. Aubert, I., Ghorayeb, I., Normand, E. & Bloch, B. Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum. *The Journal of comparative neurology* **418**, 22–32 (2000).
11. Lester, J., Fink, S., Aronin, N. & DiFiglia, M. Colocalization of D1 and D2 dopamine receptor mRNAs in striatal neurons. *Brain Res* **621**, 106–110 (1993).
12. Meador-Woodruff, J. H. *et al.* Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* **5**, 231–242 (1991).
13. Shetreat, M. E., Lin, L., Wong, A. C. & Rayport, S. Visualization of D1 dopamine receptors on living nucleus accumbens neurons and their colocalization with D2 receptors. *Journal of neurochemistry* **66**, 1475–1482 (1996).
14. Surmeier, D. J., Song, W. J. & Yan, Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **16**, 6579–6591 (1996).
15. Surmeier, D. J., Yan, Z. & Song, W. J. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. *Advances in pharmacology* **42**, 1020–1023 (1998).
16. Weiner, D. M. *et al.* D1 and D2 dopamine receptor mRNA in rat brain. *Proceedings of the National Academy of Sciences of the United States of America* **88**, 1859–1863 (1991).
17. Yung, K. K. *et al.* Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. *Neuroscience* **65**, 709–730 (1995).
18. Thibault, D., Loustalot, F., Fortin, G. M., Bourque, M. J. & Trudeau, L. E. Evaluation of D1 and D2 dopamine receptor segregation in the developing striatum using BAC transgenic mice. *PLoS one* **8**, e67219 (2013).
19. Shuen, J. A., Chen, M., Gloss, B. & Calakos, N. Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **28**, 2681–2685 (2008).
20. Bertran-Gonzalez, J. *et al.* Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **28**, 5671–5685 (2008).
21. Gangarossa, G. *et al.* Spatial distribution of D1R- and D2R-expressing medium-sized spiny neurons differs along the rostro-caudal axis of the mouse dorsal striatum. *Frontiers in neural circuits* **7**, 124 (2013).
22. Lee, S. P. *et al.* Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. *The Journal of biological chemistry* **279**, 35671–35678 (2004).
23. Perreault, M. L., Fan, T., Alijaniam, M., O'Dowd, B. F. & George, S. R. Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2. *PLoS one* **7**, e33348 (2012).
24. Perreault, M. L. *et al.* The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. *The Journal of biological chemistry* **285**, 36625–36634 (2010).
25. Perreault, M. L. *et al.* Disruption of a dopamine receptor complex amplifies the actions of cocaine. *European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology* **26**, 1366–1377 (2016).
26. Rico, A. J. *et al.* Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation. *Brain structure & function* (2016).
27. Beaulieu, J. M. & Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacological reviews* **63**, 182–217 (2011).
28. Beaulieu, J. M., Espinoza, S. & Gainetdinov, R. R. Dopamine receptors - IUPHAR Review 13. *British journal of pharmacology* **172**, 1–23 (2015).
29. Frederick, A. L. *et al.* Evidence against dopamine D1/D2 receptor heteromers. *Molecular psychiatry* **20**, 1373–1385 (2015).
30. Biezonski, D. K., Trifilieff, P., Meszaros, J., Javitch, J. A. & Kellendonk, C. Evidence for limited D1 and D2 receptor coexpression and colocalization within the dorsal striatum of the neonatal mouse. *The Journal of comparative neurology* **523**, 1175–1189 (2015).
31. Day, M. *et al.* Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. *Nature neuroscience* **9**, 251–259 (2006).
32. Shen, W. *et al.* Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. *Nature neuroscience* **10**, 1458–1466 (2007).
33. Suarez, L. M. *et al.* L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. *Biological psychiatry* **75**, 711–722 (2014).
34. Toy, W. A. *et al.* Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. *Neurobiology of disease* **63**, 201–209 (2014).
35. Fieblinger, T. *et al.* Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. *Nature communications* **5**, 5316 (2014).
36. Villalba, R. M., Lee, H. & Smith, Y. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. *Experimental neurology* **215**, 220–227 (2009).
37. Zaja-Milatovic, S. *et al.* Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. *Neurology* **64**, 545–547 (2005).
38. Stephens, B. *et al.* Evidence of a breakdown of corticostriatal connections in Parkinson's disease. *Neuroscience* **132**, 741–754 (2005).
39. McNeill, T. H., Brown, S. A., Rafols, J. A. & Shoulson, I. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. *Brain Res* **455**, 148–152 (1988).
40. Deng, Y. P., Lei, W. L. & Reiner, A. Differential perikaryal localization in rats of D1 and D2 dopamine receptors on striatal projection neuron types identified by retrograde labeling. *Journal of chemical neuroanatomy* **32**, 101–116 (2006).
41. Ariano, M. A., Stromski, C. J., Smyk-Randall, E. M. & Sibley, D. R. D2 dopamine receptor localization on striatonigral neurons. *Neuroscience letters* **144**, 215–220 (1992).
42. Escande, M. V., Taravini, I. R., Zold, C. L., Belforte, J. E. & Murer, M. G. Loss of Homeostasis in the Direct Pathway in a Mouse Model of Asymptomatic Parkinson's Disease. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **36**, 5686–5698 (2016).
43. Tepper, J. M. & Bolam, J. P. Functional diversity and specificity of neostriatal interneurons. *Current opinion in neurobiology* **14**, 685–692 (2004).
44. Rymar, V. V., Sasseville, R., Luk, K. C. & Sadikot, A. F. Neurogenesis and stereological morphometry of calretinin-immunoreactive GABAergic interneurons of the neostriatum. *The Journal of comparative neurology* **469**, 325–339 (2004).
45. Parent, A. & Hazrati, L. N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. *Brain research. Brain research reviews* **20**, 91–127 (1995).
46. Gangarossa, G. *et al.* Distribution and compartmental organization of GABAergic medium-sized spiny neurons in the mouse nucleus accumbens. *Frontiers in neural circuits* **7**, 22 (2013).
47. Hasbi, A. *et al.* Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 21377–21382 (2009).

48. Harlan, R. E., Guillot, M. & Garcia, M. M. In *The Basal Ganglia VI* Vol. 54 (eds A. M. Graybiel, M. R. DeLong & S. T. Kitai) 393–397 (Springer US, 2003).
49. Kelley, A. E. & Swanson, C. J. Feeding induced by blockade of AMPA and kainate receptors within the ventral striatum: a microinfusion mapping study. *Behavioural brain research* **89**, 107–113 (1997).
50. Stratford, T. R. & Kelley, A. E. GABA in the nucleus accumbens shell participates in the central regulation of feeding behavior. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **17**, 4434–4440 (1997).
51. Basso, A. M. & Kelley, A. E. Feeding induced by GABA(A) receptor stimulation within the nucleus accumbens shell: regional mapping and characterization of macronutrient and taste preference. *Behavioral neuroscience* **113**, 324–336 (1999).
52. Lopes, A. P. *et al.* GABAA and GABAB agonist microinjections into medial accumbens shell increase feeding and induce anxiolysis in an animal model of anxiety. *Behavioural brain research* **184**, 142–149 (2007).
53. Shen, M. Y. *et al.* Rapid anti-depressant and anxiolytic actions following dopamine D1-D2 receptor heteromer inactivation. *European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology* **25**, 2437–2448 (2015).
54. Steiner, H. & Gerfen, C. R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. *Experimental brain research* **123**, 60–76 (1998).
55. Gertler, T. S., Chan, C. S. & Surmeier, D. J. Dichotomous anatomical properties of adult striatal medium spiny neurons. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **28**, 10814–10824 (2008).
56. Moss, J. & Bolam, J. P. A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **28**, 11221–11230 (2008).
57. Descarries, L. & Mechawar, N. Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurons of the central nervous system. *Progress in brain research* **125**, 27–47 (2000).
58. Freund, T. F., Powell, J. F. & Smith, A. D. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. *Neuroscience* **13**, 1189–1215 (1984).
59. Gerfen, C. R. Molecular effects of dopamine on striatal-projection pathways. *Trends in neurosciences* **23**, S64–70 (2000).
60. Zhang, Y. *et al.* Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **33**, 11655–11667 (2013).
61. Fieblinger, T. & Cenci, M. A. Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia. *Movement disorders: official journal of the Movement Disorder Society* **30**, 484–493 (2015).
62. Nishijima, H. *et al.* Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model. *Movement disorders: official journal of the Movement Disorder Society* **29**, 336–343 (2014).
63. Ingham, C. A., Hood, S. H., van Maldegem, B., Weenink, A. & Arbuthnott, G. W. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. *Experimental brain research* **93**, 17–27 (1993).
64. Barbeau, A. The pathogenesis of Parkinson's disease: a new hypothesis. *Canadian Medical Association journal* **87**, 802–807 (1962).
65. Aosaki, T., Miura, M., Suzuki, T., Nishimura, K. & Masuda, M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. *Geriatrics & gerontology international* **10** Suppl 1, S148–157 (2010).
66. Perreault, M. L., Hasbi, A., O'Dowd, B. F. & George, S. R. The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in Basal Ganglia. *Frontiers in neuroanatomy* **5**, 31 (2011).
67. Kawaguchi, Y., Wilson, C. J. & Emson, P. C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **10**, 3421–3438 (1990).
68. Parent, A., Charara, A. & Pinault, D. Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates. *Brain Res* **698**, 280–284 (1995).
69. Gong, S. *et al.* A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. *Nature* **425**, 917–925 (2003).
70. Franklin, K. B. J. & Paxinos, G. *The mouse brain in stereotaxic coordinates*. (Academic Press, 1997).
71. Gundersen, H. J. & Jensen, E. B. The efficiency of systematic sampling in stereology and its prediction. *Journal of microscopy* **147**, 229–263 (1987).
72. Buhl, E. H. & Lubke, J. Intracellular lucifer yellow injection in fixed brain slices combined with retrograde tracing, light and electron microscopy. *Neuroscience* **28**, 3–16 (1989).
73. Dumitriu, D., Rodriguez, A. & Morrison, J. H. High-throughput, detailed, cell-specific neuroanatomy of dendritic spines using microinjection and confocal microscopy. *Nature protocols* **6**, 1391–1411 (2011).
74. Bories, C., Husson, Z., Guitton, M. J. & De Koninck, Y. Differential balance of prefrontal synaptic activity in successful versus unsuccessful cognitive aging. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **33**, 1344–1356 (2013).

Acknowledgements

This study was supported by a research grant from the Canadian Institutes of Health Research (CIHR MOP-115008) to MP, who also benefited from of a career award from the *Fonds de Recherche du Québec - Santé (FRQ-S)*. DG was the recipient of a PhD fellowship from FRQ-S. The authors are grateful to Marie-Josée Wallman for technical assistance and to Guillaume Simard for providing scripts that were used by *NeuronStudio* software to analyse morphological features of singly-injected neurons.

Author Contributions

D.G. and M.P. conceived the experiments. D.G., S.P., C.B. and M.G.S. conducted the experiments. D.G. analysed results. J.M.B. and Y.D.K. provided material, animals and important insights. A.P. and M.P. supervised all the work and wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Gagnon, D. *et al.* Striatal Neurons Expressing D₁ and D₂ Receptors are Morphologically Distinct and Differently Affected by Dopamine Denervation in Mice. *Sci. Rep.* **7**, 41432; doi: 10.1038/srep41432 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017